Literature DB >> 9199666

Modulation of protein kinases and microtubule-associated proteins and changes in ultrastructure in female rat pituitary cells: effects of estrogen and bromocriptine.

A Matsuno1, S Takekoshi, N Sanno, H Utsunomiya, Y Ohsugi, N Saito, H Kanemitsu, A Tamura, T Nagashima, R Y Osamura, K Watanabe.   

Abstract

This study focused on the intracellular signal transduction system and microtubule-associated proteins (MAPs), such as MAP-2 and Tau protein. The modulation of these proteins and their correlation with ultrastructural changes were investigated in rat pituitary prolactin (PRL) cells. Adult female Wistar rats were treated with estrogen and bromocriptine and their pituitary glands were removed for analysis of the expression of tubulin, MAP-2, Tau protein, protein kinase C (PKC), and calcium calmodulin (CaM) kinase. Western blot analysis showed that estrogen increased and bromocriptine decreased the expression of PKC alpha, beta 1, beta 2, CaM kinase alpha, beta, MAP-2, and Tau protein. MAP-2 and Tau protein, which are cytosolic proteins, being translated on free ribosomes, were associated with the membrane of whirling rough endoplasmic reticulum (RER) in estrogen-treated cells and dissociated with vesiculated RER induced by bromocriptine. These results suggested that the modulation of MAP-2 and Tau protein may reflect changes of PKC and CaM kinase, and that the quantitative changes and intracellular modulation of MAPs induced by estrogen and bromocriptine, i.e., estrogen-induced association and bromocriptine-induced dissociation of MAP-2 and Tau protein with membrane of RER, may reflect the dynamics of microtubules and are associated with structural changes in the RER and changes in the synthesis and intracellular transport of PRL.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9199666     DOI: 10.1177/002215549704500605

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  14 in total

Review 1.  Angiotensin and calcium signaling in the pituitary and hypothalamus.

Authors:  Cecilia Suárez; Isabel García Tornadú; Carolina Cristina; Jorge Vela; Arturo González Iglesias; Carlos Libertun; Graciela Díaz-Torga; Damasia Becu-Villalobos
Journal:  Cell Mol Neurobiol       Date:  2002-06       Impact factor: 5.046

2.  Environmentally relevant exposure to 17alpha-ethinylestradiol affects the telencephalic proteome of male fathead minnows.

Authors:  Christopher J Martyniuk; Kevin J Kroll; Nicholas J Doperalski; David S Barber; Nancy D Denslow
Journal:  Aquat Toxicol       Date:  2010-03-16       Impact factor: 4.964

3.  Predicting the clinical status of human breast cancer by using gene expression profiles.

Authors:  M West; C Blanchette; H Dressman; E Huang; S Ishida; R Spang; H Zuzan; J A Olson; J R Marks; J R Nevins
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-18       Impact factor: 11.205

4.  MAP-2 expression in the human adenohypophysis and in pituitary adenomas. An immunohistochemical study.

Authors:  Fabio Rotondo; Kenichi Oniya; Kalman Kovacs; C David Bell; Bernd W Scheithauer
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

5.  Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer.

Authors:  Roman Rouzier; Radhika Rajan; Peter Wagner; Kenneth R Hess; David L Gold; James Stec; Mark Ayers; Jeffrey S Ross; Peter Zhang; Thomas A Buchholz; Henry Kuerer; Marjorie Green; Banu Arun; Gabriel N Hortobagyi; W Fraser Symmans; Lajos Pusztai
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-24       Impact factor: 11.205

6.  Expression and silencing of the microtubule-associated protein Tau in breast cancer cells.

Authors:  Tatiana Spicakova; Maureen M O'Brien; George E Duran; Alejandro Sweet-Cordero; Branimir I Sikic
Journal:  Mol Cancer Ther       Date:  2010-11-09       Impact factor: 6.261

7.  Predictive value of microtubule-associated protein Tau in patients with recurrent and metastatic breast cancer treated with taxane-containing palliative chemotherapy.

Authors:  Jie Zhou; Shikun Qian; Hongsheng Li; Weixing He; Xiaojun Tan; Qiong Zhang; Guodong Han; Guiquan Chen; Rongcheng Luo
Journal:  Tumour Biol       Date:  2015-03-14

8.  The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells.

Authors:  Hirokuni Ikeda; Naruto Taira; Fumikata Hara; Takeo Fujita; Hiromasa Yamamoto; Junichi Soh; Shinichi Toyooka; Tomohiro Nogami; Tadahiko Shien; Hiroyoshi Doihara; Shinichiro Miyoshi
Journal:  Breast Cancer Res       Date:  2010-06-28       Impact factor: 6.466

9.  Inhibitory effects of anti-VEGF antibody on the growth and angiogenesis of estrogen-induced pituitary prolactinoma in Fischer 344 Rats: animal model of VEGF-targeted therapy for human endocrine tumors.

Authors:  Katsuhiro Miyajima; Susumu Takekoshi; Johbu Itoh; Kochi Kakimoto; Takashi Miyakoshi; Robert Yoshiyuki Osamura
Journal:  Acta Histochem Cytochem       Date:  2010-04-07       Impact factor: 1.938

10.  Estrogen-induced activation of mitogen-activated protein kinase in cerebral cortical explants: convergence of estrogen and neurotrophin signaling pathways.

Authors:  M Singh; G Sétáló; X Guan; M Warren; C D Toran-Allerand
Journal:  J Neurosci       Date:  1999-02-15       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.